Australia's most trusted
source of pharma news
Posted 31 July 2024 AM
ASX-listed LTR Pharma is ploughing big dollars into launch plans for its game-changing nasal spray for the treatment of erectile dysfunction as it looks to secure a partnership deal with Big Pharma for global commercialisation of the product.
The company said it will use $10.5 million from a special funding raising to expedite commercialisation of its product Spontan, channelling $2 million into sales and marketing, $1 million into a telemedicine consumer website, $2 million to expand its R&D pipeline and $1.4 million on regulatory studies. The balance will go into working capital and to cover the costs of the offer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.